AL102-503
12 evidence topics · 1 source
Objective
Pharmacokinetics, safety, and tolerability in hepatic impairment
Location and study date
Registry status, dates, and sites
| Study characteristic | Quoted record |
|---|---|
| Protocol number | “AL102-503” |
| Sponsor | “Immunome, Inc.” |
| Overall status | “Completed” |
| Study start (actual) | “2025-03-07” |
| Primary completion (actual) | “2025-11-05” |
| Study completion (actual) | “2026-03-06” |
| First posted | “2025-02-24” |
| Last update posted | “2026-03-10” |
| Sites | “Orlando Clinical Research Center”; “The Texas Liver Institute” |
Study design
Open-label, single-dose, parallel-group design with matched controls
Conditional enrollment of participants with severe hepatic impairment
Registry design fields
| Study characteristic | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Intervention model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Primary purpose | “Other” |
Eligibility criteria
Healthy matched participants aged 18 to 84 years
Treatment
Single oral dose of varegacestat on day 1
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Primary endpoints: AUC and Cmax of varegacestat and metabolite
Secondary endpoints: safety and tolerability
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (actual) | “35” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- AL102-503 is known only from its registry record. The record lists the study as “Completed”, with study completion on 2026-03-06, and shows no posted results; no publication, congress presentation, or Immunome document reporting its results was identified, so varegacestat exposure in hepatic impairment is unknown from public sources.
- The registry gives the actual enrollment as 35 participants but not their distribution across the healthy, mild, moderate, and severe hepatic impairment groups. Enrollment of the severe group (Child-Pugh C) was planned only “if appropriate”, contingent on data from the first three groups.
- The design is open label with a single oral dose, and the registry record does not state the dose.